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Emerging regenerative medicine and tissue engineering
strategies for Parkinson’s disease
James P. Harris1,2, Justin C. Burrell1,2,3, Laura A. Struzyna1,2,3, H. Isaac Chen1,2, Mijail D. Serruya4, John A. Wolf1,2, John E. Duda2,5,6* and
D. Kacy Cullen1,2,3*
Parkinson’s disease (PD) is the second most common progressive neurodegenerative disease, affecting 1–2% of people over 65. The
classic motor symptoms of PD result from selective degeneration of dopaminergic neurons in the substantia nigra pars compacta
(SNpc), resulting in a loss of their long axonal projections to the striatum. Current treatment strategies such as dopamine
replacement and deep brain stimulation (DBS) can only minimize the symptoms of nigrostriatal degeneration, not directly replace
the lost pathway. Regenerative medicine-based solutions are being aggressively pursued with the goal of restoring dopamine levels
in the striatum, with several emerging techniques attempting to reconstruct the entire nigrostriatal pathway—a key goal to
recreate feedback pathways to ensure proper dopamine regulation. Although many pharmacological, genetic, and optogenetic
treatments are being developed, this article focuses on the evolution of transplant therapies for the treatment of PD, including fetal
grafts, cell-based implants, and more recent tissue-engineered constructs. Attention is given to cell/tissue sources, efficacy to date,
and future challenges that must be overcome to enable robust translation into clinical use. Emerging regenerative medicine
therapies are being developed using neurons derived from autologous stem cells, enabling the construction of patient-specific
constructs tailored to their particular extent of degeneration. In the upcoming era of restorative neurosurgery, such constructs may
directly replace SNpc neurons, restore axon-based dopaminergic inputs to the striatum, and ameliorate motor deficits. These
solutions may provide a transformative and scalable solution to permanently replace lost neuroanatomy and improve the lives of
millions of people afflicted by PD.
npj Parkinson’s Disease             (2020) 6:4 ; https://doi.org/10.1038/s41531-019-0105-5
OVERVIEW: REGENERATIVE MEDICINE
The field of regenerative medicine encompasses the use of cell
replacement strategies and tissue engineering to promote
regeneration and functional restoration following injury or
disease.1 Cell delivery strategies may replace lost cells in cases
where endogenous cells are insufficient or dysfunctional (e.g., new
neurons). Tissue engineering techniques generally combine
aspects of biomaterial scaffolds and cell replacement techniques
to create a three-dimensional (3-D) environment to influence cell
(native and/or implant) behavior such as phenotype, architecture,
migration, and survival. Indeed, biomaterials can provide 3-D
structure for host cell infiltration, differentiation, and organization,
and may also serve as a means for drug administration (e.g.,
controlled release). In the central nervous system (CNS), both cell
replacement and tissue engineering strategies are being vigor-
ously pursued to facilitate regeneration of native tissue and/or to
directly restore lost function based on permanent structural
integration.2–5 Although the primary long-term goal for the
treatment of Parkinson’s disease (PD) is to develop a means to
arrest the progressive neurodegenerative pathology, the objective
of the field of regenerative medicine is to advance restorative
treatments to functionally replace and/or reconstruct neuronal
circuitry that has succumbed to the disease. This article reviews
the historic, current, and emerging regenerative medicine
strategies for PD, emphasizing the importance of reconstructing
the entire nigrostriatal pathway for consistent and durable
recovery of function. Further, we will discuss the challenges
associated with translating these solutions into clinical practice.
PARKINSON’S DISEASE
Epidemiology and societal burden
PD is a progressive neurodegenerative disease that causes
significant morbidity across a prolonged and progressive disease
course. PD is characterized by resting tremor, bradykinesia
(slowness of movement), rigidity, and other symptoms that
decrease quality of life, ultimately leading to significant disability
via the inability to control motor function.6,7 In the United States,
50,000–60,000 cases are diagnosed each year with a prevalence of
over one million people.7 As the disease affects 1–2% of people
over 65, its prevalence is expected to double in the next 20 years.8
The cost of PD is estimated to be ~$35 billion per year in the
United States alone.9 Recent studies have estimated that arresting
PD progression would result in net monetary benefits of almost
$450,000 per patient, and if PD progression was slowed by 20%, a
benefit of over $75,000 per patient would be realized.9
Pathophysiology and neuropathology
Motor symptoms of PD are caused by the selective loss of
dopaminergic neurons in the substania nigra pars compacta
(SNpc) projecting to the dorsal striatum, which is composed of the
1Center for Brain Injury & Repair, Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 2Center for Neurotrauma,
Neurodegeneration & Restoration, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA. 3Department of Bioengineering, School of Engineering
and Applied Science, University of Pennsylvania, Philadelphia, PA, USA. 4Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA. 5Department of
Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 6Parkinson’s Disease Research, Education, and Clinical Center (PADRECC), Michael J.
Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA. *email: john.duda@va.gov; dkacy@pennmedicine.upenn.edu
www.nature.com/npjparkd













caudate and putamen (see Fig. 1 for an overview of the relevant
neuroanatomy). SNpc degeneration is thought to result from the
formation of Lewy bodies and Lewy neurites, inclusions in cytoplasm
and processes, respectively.10 The primary components of Lewy
pathology are filaments of α-synuclein, a neuronal protein
normally found in synaptic terminals.11 Lewy pathology also
occurs outside of the SNpc and striatum, including in the olfactory
bulb, medulla, pons, spinal cord, and peripheral autonomic
system, and in later stages of PD, the midbrain, amygdala,
hippocampus, and several other cortical regions.12,13 At the time
of motor symptom onset, at least 60% of SNpc cells have
degenerated.10 There are several theories as to why dopaminergic
neurons are preferentially impacted, but many believe that a
combination of factors including structure, function, and meta-
bolic needs make dopaminergic neurons particularly vulnerable to
the pathophysiology of PD.14
Non-motor symptoms associated with PD affect nearly the
entire body, encompassing a wide range of manifestations
including sensory deficits and pain, irregular sleep cycle patterns
and dream re-enactment behavior, cognitive decline, depression,
anxiety, apathy, psychosis, urinary dysfunction, constipation, and
other autonomic dysfunctions.15,16 Although PD is commonly
associated with motor symptoms, some non-motor symptoms,
such as olfactory dysfunction and dream re-enactment behavior,
can present before the onset of the classic motor symptoms of PD,
whereas others manifest at later stages, such as cognitive decline
and neuropsychiatric disorders.17 Widespread α-synuclein pathol-
ogy is often observed throughout the nervous system in regions
associated with the manifestation of non-motor symptoms,
however the exact mechanisms remain unclear.18 Growing
evidence has implicated neurotransmitter depletion (e.g., nora-
drenergic, serotonergic, and cholinergic) in multiple intercon-
nected CNS pathways, specifically between the striatum,
prefrontal cortex, limbic system, and spinal cord, in the
manifestation of many non-motor symptoms of PD.19
Importance of the nigrostriatal pathway and implications of its loss
As SNpc neurons send long axonal projections to the striatum, the
stereotypical neurodegeneration that occurs in PD deprives the
striatum of crucial dopaminergic inputs and thereby interrupts
important motor feedback pathways. The nigrostriatal pathway is
a major component of the basal ganglia, the interconnected
structures within the brain involved in motor control (Fig. 1). The
main structures in the basal ganglia circuitry are the dorsal
striatum (caudate nucleus and putamen), the core of the nucleus
accumbens, the globus pallidus, the subthalamic nucleus (STN),
and the substantia nigra. The primary input target of the basal
ganglia is the striatum, which integrates the incoming sensor-
imotor information via projections from the neocortex, intralami-
nar nuclei of the thalamus, and midline nuclei of the midbrain.
Output projections from the internal segment of the globus
pallidus (GPi) and pars reticulata of the substantia nigra (SNpr) are
modulated by two basal ganglionic circuits, which are referred to
as the “direct” and “indirect” pathways.20 The direct pathway
serves to increase movement with inhibitory projections from the
striatum to the SNpr and GPi. The indirect pathway serves to
decrease movement with inhibitory projections to the external
segment of the globus pallidus (GPe), which in turn sends
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Fig. 1 Overview of basal ganglia neuroanatomy. A schematic overview of the primary motor circuits in the basal ganglia, the indirect (left)
and direct (right) pathways. Note, pathways crossing sides does not imply decussation, rather the contralateral connections separate the
indirect and direct pathways. Excitatory connections are depicted in green with triangle ends, inhibitory connections are depicted in red with
“T” ends. Not all connections are depicted, including but not limited to, all connections from thalamus to cortex, all connections from cortex
to striatum, connections to/from caudate nucleus (tail), connections from cortex to brainstem, and inputs to SNpc (pictured in the inset). Inset:
a schematic overview of inputs to SNpc found in literature. The PPN is located caudal to the substantia nigra and inputs are depicted as such.
Inputs from the caudate nucleus (tail) is not pictured, and not all inputs from the cortex are depicted. Merging of signals from the cortex or
caudate/putamen are done for illustrative purposes. D1; D1 receptors; D2; D2 receptors; DA dopamine; ENK enkephalin; GLU glutamate;
NUC nucleus; PPN pedunculopontine nucleus; SP substance P; SUB substantia.
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inhibitory projections to the STN that sends excitatory projections
to the GPi and SNpr.21 These pathways are antagonistic: the direct
pathway leads to motor facilitation, and the indirect pathway
suppresses unwanted motor movement (motor cessation).
As such, a main component of the basal ganglia motor circuit is
the nigrostriatal pathway with dopaminergic projections originat-
ing from neurons in the SNpc. The projections comprise the highly
dense axonal arborization found mostly in the striatum with some
collateral arborization in the GPe. Dopamine-releasing axons in
the nigrostriatal pathway synapse onto GABAergic medium spiny
neurons in the striatum. In the direct pathway, the terminals
synapse to D1 receptors, and in the indirect pathway, the
terminals synapse to D2 receptors. Dopamine release activates
the direct D1-receptor-mediated pathway that ultimately facil-
itates motor movement. In non-pathologic conditions, the cortex
activates the indirect pathway with a smaller contribution of
inhibition through SNpc dopamine release on D2-receptor cells in
the striatum. In PD, the degeneration of SNpc dopamine neurons
shifts the balance of direct and indirect pathways. The net result of
both pathways is inhibitory cells in the GPi/SNpr are more active
to create a stronger inhibition of the thalamus that culminates in
less activation of the motor cortex.
The diagram of the indirect and direct pathways (Fig. 1) is
meant to approximate the primary pathways for motor move-
ment, and includes an insert containing an important aspect often
left out of published pathway diagrams: input to the SNpc, which
modulate basal ganglia activity, thus closing the feedback loop
(Fig. 1 insert). Indeed, the literature indicates the presence of a
wide array of inputs into the SNpc including GABAergic from the
caudate/putamen, glutamatergic from the cortex and STN,
glutamatergic and cholinergic from pedunculopontine nucleus,
and GABAergic input from the SNpr.22–25 It is probable that these
inputs to the SNpc are vital for highly functioning motor feedback
circuits.26,27
The striatum is further organized into two distinct compart-
ments comprised of dendrite and local axon collaterals known as
the striosomes and the matrix.28 The matrix compartment relays
information from sensorimotor input and output neurons to the
GPi and SNpr via the direct and indirect pathways. Striosomes,
also known as patch compartments, are widely distributed regions
within the striatum comprising ~15% of the volume in the
striatum. The striosome compartments form an interconnected
3-D labyrinthine network within the striatum. Striosome neurons
are thought to modulate the entire dorsal striatum via the
inhibitory projections to the dopaminergic neurons in the SNpc
(not pictured in Fig. 1).
Long-projecting axons from SNpc neurons exhibit an exquisite
arbor in the striatum to release dopamine at highly dense
varicosities along the axon, which are organized en passant with
neighboring neuronal compartments (Fig. 2). Dopamine has a
rapid half-life, which limits its sphere of influence. However, the
highly dense arborization of dopaminergic neurons provides
overlapping and redundant innervation of the striatum, which
leads to increased temporal and spatial effects compared with
what can be achieved from a single dopaminergic neuron.29
Detailed anatomical work in rodents showed that a single
dopaminergic neuron innervates, on average, 2.7% of the neurons
in one striatum (e.g., ~75,000 out of 2,790,000 striatal neurons in
one hemisphere of the rodent brain).28 Moreover, because of the
redundant overlapping arborization, it is estimated that a single
striatal neuron is under the influence of 95–194 dopaminergic
neurons from the SNpc. Consequently, this highly redundant
organization might contribute to the clinical presentation of PD;
patients only develop symptoms of Parkinsonism following an
extensive loss of dopaminergic neurons (>60%).28–30 The com-
plexity and nuances of the basal ganglia circuitry and the
widespread innervation of a single nigrostriatal axon, let alone
all nigrostriatal inputs, warrant thoughtful consideration regarding
techniques for adequate circuit reconstruction.
HISTORIC AND CURRENT TREATMENTS FOR PD
Evolution of care: pharmacological interventions to
neuromodulation
As far back as the 1940s, the advent of the stereotactic head frame
allowed the targeting of subcortical structures with great
precision.31 Surgeons discovered that ablation or lesion therapy
could modulate brain activity and ameliorate the symptoms of
PD.32 However, the discovery of levodopa (or other dopamine
agonists) led to a shift away from surgical therapy to chronic
pharmaceutical treatment.33 These agents attempt to compensate
for the underproduction of dopamine owing to cell loss. In the
Fig. 2 Rich dopaminergic axon arborization in the striatum.
Camera lucida reconstruction of a dorsal SNpc neuron. a The axon
fibers in the striatum and b dendrites in the SNpc were projected
onto a parasagittal plane and superimposed from the medial side.
c The dorsal and frontal views of the intrastriatal axonal arborization
were reconstructed and compared with the medial view. Red and
blue lines in the striatum indicate the axon fibers located in the
striosome and matrix compartments, respectively. Red fibers at the
most rostral portion in a were mostly located in the MOR-positive
subcallosal streak. d The axon gave rise to only minor collaterals in
the external segment of the GPe. ac anterior commissure; cc corpus
callosum; cp cerebral peduncle; CPu caudate–putamen (neostria-
tum); Hpc hippocampus; ic internal capsule; LV lateral ventricle; ml
medial lemniscus; MOR μ-opioid receptor; ot optic tract; SNc
substantia nigra pars compacta; SNr substantia nigra pars reticulate;
STh subthalamic nucleus; str superior thalamic radiation; Th
thalamus; ZI zona incerta. (Image and caption adapted from
Matsuda et al.28 and reprinted with permission from publisher).
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early 1990s, Laitinen et al. reintroduced the posteroventral
pallidotomy and reported significant improvements for all motor
complications of PD.34 During pre-thalamotomy mapping studies,
high-frequency electrical stimulation ameliorated PD symptoms,
leading to the development of DBS.35 By the mid-1990s, DBS of
the GPi and STN was also shown to be effective. Indeed, in
appropriately selected patients where levodopa-related complica-
tions are disabling, modulation of brain function via DBS of the
GPi or STN has been shown to be superior to continued medical
management.32 In many cases, pharmacological treatments are
the first step in treatment, followed by DBS as a second step.
Often, DBS patients continue levodopa or other pharmacological
treatments, although often at a lower dose.
Although these treatments have led to significant improve-
ments in movement disabilities and improved the quality of life
for patients with PD, they are treating symptoms resulting from
the loss of dopaminergic input to the striatum rather than
resolving the underlying neurodegeneration. In addition, there are
often unwanted side effects. For instance, DBS stimulation may
detrimentally impact cognition and speech.36 Moreover, any
current treatment regimen—pharmaceutical management, DBS,
or a combination of the two—often fails to give the same clinical
benefit over time. The lack of long-term efficacy is generally
attributed to one of two issues: (1) the advent of adverse side
effects (e.g., dyskinesias, motor fluctuations, behavioral addictions,
and/or impulse control disorders),37 or (2) the ongoing degenera-
tion of nigrostriatal neurons decreasing clinical benefits. As such,
even with state-of-the-art management, the average duration
from minimal disability to confinement to bed or wheelchair is
~13 years.9
New pharmaceutical therapies that focus on neuroprotection
are being developed, although to date, there are no proven
therapies to slow progression of disease.38 In addition, these
treatments would not restore innervation to the striatum, as they
would not replace SNpc dopaminergic neurons that had
degenerated before the onset of motor symptoms.10 Therefore,
a method to diagnose PD pathology before the onset of motor
symptoms would be necessary for these pharmacological
methods to maintain motor function.39 Although there is growing
evidence that non-motor symptoms have a key impact on quality
of life, only a few large randomized clinical trials have focused on
management of non-motor symptoms.16 Dopaminergic replace-
ment strategies are ineffective for treatment of most of the non-
motor symptoms, and are commonly associated with non-motor
side effects including somnolence, orthostatic hypotension, visual
hallucinations, and nausea.40
Gene therapies to relieve PD symptoms have recently reached
clinical trials evaluating the efficacy and safety of delivering
vectors with genes encoding for overexpression of (1) glutamic
acid decarboxylase in the subthalamic nuclei to increase the GABA
basal tone,41,42 (2) enzymes to increase endogenous striatal
dopamine synthesis or conversion of L-dopa to dopamine,43 and
(3) neurturin—a ligand similar to glial cell line-derived neuro-
trophic factor (GDNF) that has been shown to enhance survival
and outgrowth of dopaminergic neurons.44,45 To date, out of these
gene therapy clinical trials, only the vector with the gene
encoding for increased production of glutamic acid decarboxylase
has demonstrated beneficial motor function.46 Therefore,
although gene therapy might be a promising strategy, develop-
ment of an effective treatment requires more research.
Cell transplant-based treatments
Prior to the 1970s, it was widely believed that restorative
treatments for neurodegenerative diseases of the CNS were not
possible. However, two articles published in the same year
demonstrated that fetal mesencephalic grafts rich in dopaminer-
gic neurons could ameliorate Parkinsonism symptoms in rodent
models.47,48 Since then, many studies have examined the
potential of cell transplant-based treatments to restore dopamine
in the striatum and ameliorate motor deficits of PD.49 As of 2004,
over 350 patients had received cell replacement therapies, and in
many cases, patients were tapered off drugs and witnessed a
decrease in motor symptoms.50 Successful fetal tissue grafts have
survived over two decades in some patients despite ongoing PD
pathology.51 Indeed, long-term survival of grafted dopaminergic
neurons with extensive putamenal dopaminergic innervation
was reported in PD patients at postmortem.51,52 In addition,
18F-fluorodopa imaging demonstrated robust dopaminergic
uptake within the striatum. Clinical trials have indicated beneficial
results from cellular grafts when methods sustain a novel
population of at least 80,000 dopaminergic neurons, although,
in a recent study, motor benefits were observed with only 40,000
neurons surviving after 24 years.52,53
Although inconsistent, clinical improvements, such as
decreased motor symptoms, were observed in some cases;
however, widespread clinical adoption of tissues grafts has been
stymied by several notable limitations. A subset of patients
had adverse side effects or no significant improvements.50
Moreover, grafts were sourced from fetal tissue, and the variability
of source tissue likely contributed to some trials showing limited
to no efficacy. In addition, multiple fetal donors (typically 3–5)
must be pooled to source a sufficient number of cells for one
patient, which may contribute to the heterogeneity of outcomes
and likely indicates a lack of material for widespread clinical usage.
This is exacerbated by ethical concerns associated with fetal tissue
that make access difficult in some instances, thereby limiting
procedures. Also, trials have had varied preparation, storage, and
immunosuppression regimes that may have affected the health of
the grafts, again creating a source of variability and likely affecting
efficacy. Thus, fetal grafts have inherent issues with consistency
and requirements for immunosuppression.54
Another concern is that the majority of these studies involved
cellular graft implantations in the striatum, not the SNpc—the
location of dopaminergic neurons naturally providing input to the
striatum. Whereas cells implanted into the striatum may create
new “factories” for dopamine, these cells do not receive their
normal inputs to control their activity, potentially resulting in
dysregulated dopamine release and related side effects. As
discussed previously, the SNpc receives a wide range of inputs,
and these inputs are thought to be important for restoring the full
motor circuit.26,27 The tradeoffs between different options for
placement of cells/grafts is covered in more depth below, but
complete function of the motor control system relies on well-
controlled feedback loops that fine-tune dopamine levels.
Although significant progress has been made, fetal tissue grafts
do not appear to present a viable or sustainable strategy to repair
the nigrostriatal pathway and replicate both the outputs and
inputs for dopamine regulation to the striatum from the SNpc.
However, success of fetal grafts in PD patients demonstrates the
potential for dopaminergic neuron transplants to provide long-
term benefits, provided there are improvements in cell/tissue
supply, consistency, and ideally, actual recreation of the nigros-
triatal pathway.
REGENERATIVE MEDICINE APPROACHES TO TREATING PD
The challenge of CNS regeneration
The extraordinary computational capabilities of the human brain
rely on vast axonal connections spanning long distances that form
sophisticated neural circuits and enable profound parallel proces-
sing, often referred to as the connectome.55 Degeneration and
disconnection of these axonal pathways as well as localized
neuronal degeneration frequently occur in many CNS disorders,
including traumatic injury, stroke, PD, and others.56 Unfortunately,
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functional regeneration rarely occurs in the CNS and neurogenesis
is restricted to a few distinct domains, such as the subventricular
zone and the dentate gyrus of the hippocampal formation. In the
majority of the CNS, natural regeneration of long axon pathways
does not occur, mainly owing to endogenous inhibition of axon
growth, absence of directed guidance to far distant targets, and
loss of intrinsic capacity for long outgrowth in mature neurons.
The lack of neurogenesis and correctly targeted axonal regrowth
are key limitations in endogenous CNS regeneration and repair,
thereby resulting in diminished recovery and continued functional
deficits.
Regenerative medicine
The field of regenerative medicine is pursuing novel approaches
to develop cellular and tissue constructs to facilitate regeneration
and/or restore function following injury, aging, or disease. These
techniques are being applied to address the limitations in repair
and regeneration in the CNS, and in the particular case of PD, aim
to build upon the benefits of cellular grafts seen in human
patients. Using novel biomaterials, tissue culture techniques, and
knowledge from previous experiments, the concerns associated
with cellular grafts, such as consistency of cells, need for
immunosuppression, placement of cells, and source of tissue
(supply and ethics), can be addressed.
Design goals to restore the nigrostriatal pathway
The pioneering work from the 1970s and 1980s demonstrated the
potential for allografted fetal tissue to improve striatal dopamine
levels in some patients with PD. These studies also paved the way
to design criteria for cell-based therapies prior to clinical trials
including:
(a) Long-term survival of dopaminergic neurons into the host
striatum with robust fiber outgrowth in the adult rodent
brain.57
(b) Afferent and efferent synaptic integration with the host
rodent brain (i.e., receiving local inputs from the host brain
and forming connections with host striatal end target)
following implant of dopaminergic neurons into a cortical
cavity.58,59
(c) Adequate dopamine release in a controlled fashion follow-
ing intrastriatal grafts in adult rats.60
(d) Amelioration of motor deficits in rodent models of PD
following intracerebral grafting of dopaminergic neurons.61
To actually recapitulate the native anatomy of the nigrostriatal
pathway would call for grafts, originating in the substantia nigra
and terminating in the striatum. Initially, for proof-of-concept
studies in rats, the literature suggests a requirement of ≥1200
morphologically healthy dopaminergic neurons with a unidirec-
tional axonal architecture and ≥5–6mm in length that result in
dopamine release in the range of 50–100 nM in the striatum for
functional benefits to be seen.62,63 Based on human fetal graft
studies, these numbers translate to 40,000–80,000 healthy
dopaminergic neurons, unidirectional axonal architecture of
≥3–5 cm in length, and dopamine release of ≥7 ng/mg of tissue
for nigrostriatal pathway restoration in humans (Table 1).53,64 In
addition, owing to post transplant attrition, pre-transplant
constructs will likely require a greater number of dopaminergic
neurons (e.g., ≥2400 healthy dopaminergic neurons with 50%
survival would result in ≥1200 neurons), although the exact rates
of attrition would require further research.
To sidestep issues with tissue grafts, researchers have studied
myriad cell-based therapies to treat PD.65 Cell replacement
strategies use endogenous or exogenous cell sources, including
stem cells, and are similar in concept to the tissue graft techniques
but generally involve cell dissociation and/or expansion.4 The
usage of stem cells allows for therapies that can include secretion
of neuroprotective factors as well as self-renewing cells that give
rise to additional neurons or other cell types.3 To restore the entire
nigrostriatal pathway with appropriate inputs and outputs remains
a considerable challenge, as implantation of only dissociated cells
cannot restore the key anatomic features of damaged pathways—
notably long axon tracts projecting to proper anatomical
structures. Key considerations include (1) cell source, (2) location
of the transplant, and (3) strategy to facilitate sufficient and
appropriate axonal outgrowth to the striatum (summarized in
Fig. 3).
For cell replacement strategies that aim to restore the entire
nigrostriatal pathway, the first key consideration is the cell source
of the graft material. The development of the 6-hydroxydopamine
(6-OHDA)-lesioned rodent model of PD, which selectively and
irreversibly degenerates dopaminergic neurons in the lesioned
nigrostriatal pathway, has led to various approaches to determine
whether restoration of dopaminergic tone could ameliorate
Parkinsonian motor symptoms.47,48 Moreover, several grafting
strategies using different dopamine-producing tissues have been
evaluated in clinical trials, such as adrenal medullary cells (AMCs),
sympathetic ganglia, carotid body cells, retinal pigmentary
epithelial cells linked to microcarriers, and porcine ventral
mesencephalon tissue.66 However, the most-effective transplanta-
tion strategy has been with human fetal mesencephalic tissue.
Preclinical rodent studies have shown that transplanted dopami-
nergic neurons from human fetal mesencephalic grafts can
innervate the dopamine-deprived striatum, receive inputs from
host neurons, and diminish rotational behavioral symptoms.67,68
These developments led to clinical trials using human ventral
mesencephalic tissue that demonstrated survival of grafted
dopaminergic neurons up to 24 years after transplantation,
integration with the brain circuitry, and improvement in motor
symptoms.51,52,69–72 Despite these promising findings, clinical
improvement has varied across different trials likely owing to
inadequate standardization of patient enrollment, tissue harvest,
graft location, surgical implantation, and immunosuppression.73
Although the early preclinical experience and clinical successes
using fetal grafts has been crucial to establish the potential for a
cell transplantation strategy in PD, further developments have
been challenging owing to ethical concerns and limited tissue
availability.
Alternative, non-fetal cell source candidates have been devel-
oped to avoid these concerns with the goal of attaining the same
outcomes as the early fetal transplantation studies. Non-neuronal,
catecholamine-producing cell sources, such as AMCs and retinal
pigmentary epithelial cells, have been considered as a potential
alternative to fetal grafts by producing and secreting dopamine in
the striatum, thereby restoring motor function.49 However, these
grafts did not demonstrate the same potential to restore the
dopamine levels in the striatum and ameliorate behavioral deficits
as the fetal grafts in preclinical studies; therefore, it was not
surprising that clinical trials evaluating non-neuronal cell sources
did not result in significant motor improvements compared with
the relatively successful human fetal ventral mesencephalic
grafts.66 These experiments illustrate the importance of validating
potential grafting strategies by demonstrating robust cell survival,
host integration, and dopamine release in animal models before
clinical trials.
Building on the knowledge gained from transplantation studies
using fetal grafts or non-neuronal cell types, it has become clear
that a successful grafting strategy likely requires use of a cell
source capable of generating authentic dopaminergic neurons
that resemble those found in the SNpc and can re-establish lost
striatal innervation.74 Indeed, various approaches have been
developed to generate dopaminergic-like neurons from alter-
native cell sources, such as embryonic stem cells (ESCs), induced
pluripotent stem cells (iPSCs), expanded neural precursor cells
J.P. Harris et al.
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(NPCs), mesenchymal stem cells (MSC), and direct neuronal
reprogramming.49
Pluripotent stem cells are a promising alternative to fetal ventral
mesencephalon grafts owing to their capability to provide a
potentially unlimited source of any cell type. Advancements in the
fields of stem cell neurobiology have led to the generation of two
different types of pluripotent stem cells: (1) ESCs derived from the
inner cell mass of early-stage embryos and (2) iPSCs derived from
de-differentiated somatic cells. Early studies demonstrated that
ESC-derived dopaminergic neurons were capable of surviving in
an adult rodent brain, however, incomplete differentiation led to
increased risk of tumor formation and neural overgrowth.75
Recent studies appear to have resolved these issues with
improved differentiation protocols and cell culture techniques.76,77
However, despite these advancements, widespread development
of ESC-derived dopaminergic cell therapies has remained limited
for the same inherent reasons as fetal transplantations; lack of
tissue availability and ethical concerns.
The discovery of somatic cell de-differentiation has led to
increased interest in iPSCs as a promising alternative cell source
for future PD therapies owing to the potential of generating
patient-specific iPSC-derived dopaminergic neurons.65 Although
early preclinical data did not demonstrate similar outgrowth or
functional restoration in rodent and non-human primate (NHP)
models of PD compared with fetal grafts, advancements in
developmental neurobiology led to the discovery that dopami-
nergic neurons are derived from floor plate cells, not neuroe-
pithelial progenitors like every other neuron in the brain.78 This
new finding enabled the development of novel molecular
differentiation techniques for generating more “authentic-like”
dopaminergic neurons resembling those found in the SNpc.79
Furthermore, human ESC- and iPSC-derived dopaminergic neu-
rons generated with these refined differentiation protocols seem
to have solved the earlier issues with tumorgenicity, and enabled
long-distance targeted striatal innervation.76,77,80 Although iPSC-
derived neurons have been shown to survive transplantation,
variable amounts of neurite outgrowth has been reported, which
is likely responsible for inconsistent functional restoration.81
Neural stem cells (NSCs) expanded from ESCs and iPSCs have
been investigated as an alternative source for neural cell
replacement treatment for PD owing to their multipotent and
self-renewing properties.82 Unlike ESCs and iPSCs, NSCs have
limited differentiation capability and are fated towards a brain cell
Table 1. Target dopaminergic neuron densities and dopamine
production.
Rat Human
No. of dopaminergic neurons required:
Dopamine cell therapeutic threshold ≥1200–2400a ≥40,000–80,000b
Therapeutic dopamine production 50–100 nMc 7 ng/mg of tissued
aData from Isacson, Bjorklund63
bData from Bjorklund and Lindvall53
cData from Robinson, Venton et al.62
dData from Kish, Kalasinsky et al.64
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Fig. 3 Overview of regenerative medicine-based repair strategies for PD. A schematic overview of the possible repair strategies for the
nigrostriatal pathway. The figure depicts the same circuit diagram schematic shown in Fig. 1 with circuit connections removed. The top left
inset includes the various cell sources used (Consideration 1). The red, green, and yellow arrows indicate the various locations that cells have
be implanted (Consideration 2). The inset to the right shows a preformed construct solution to restore the nigrostriatal pathway, including
dopaminergic cell bodies in the SNpc, the inputs to those dopaminergic cells from other neural structures, and their long axonal outputs to
the striatum. NUC nucleus; SUB substantia.
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phenotype, reducing the likelihood for tumor growth.83 NSCs have
been shown to be an effective neural repair strategy in preclinical
models of injury owing to their inherent ability to provide
neuroprotection, decrease immunoreactivity, and secrete neuro-
trophic factors, such as glial-derived neurotrophic factor and
brain-derived neurotrophic factor.84 Previous work has also shown
that NSCs can differentiate into dopaminergic-like cells, survive
transplantation, integrate with the host architecture, and
improve functional recovery.85 Another promising direction is
the development of an autologous cell source for transplantation
using patient-specific iPSC-derived NSCs.82 Although intriguing,
expansion of NSCs has remained challenging and likely requires
further refinement for clinical trials. Moreover, further safety and
efficacy preclinical studies are necessary to reduce the likelihood
for graft and/or differentiation failure.86
MSCs are multipotent, non-hematopoietic stem cells capable of
self-renewal that typically arise from bone marrow and differ-
entiate into adipocytes, osteoblasts, and chondroblasts, and have
been reported to elicit an anti-inflammatory effect.87 Elevated
neuroinflammatory responses have been implicated in neurode-
generative diseases, such as PD and Alzheimer’s disease.88 These
findings have led to increased interest in MSCs as a potential cell
source candidate owing to their immunomodulatory effect.89
Indeed, MSCs have demonstrated the capability to differentiate
into astrocyte-like cells that secrete neurotrophic factors and
ameliorate the motor deficits in a rodent model of PD.90 In
addition to immunomodulation, MSCs or MSCs differentiated into
a neuron-like phenotype have been reported to migrate across
the corpus callosum to a 6-OHDA-lesioned SNpc and striatum
when initially transplanted in the contralateral hemisphere.91
However, it is unclear whether the cells are attracted to the lesion
or the acute inflammation at the injection site.92
Direct neuronal reprogramming has recently become an
interesting cell source candidate due to the potential for
generating dopaminergic neurons from somatic cells by adding
transcription factors for cell lineage conversion.93 This strategy
could theoretically provide autologous dopaminergic neurons
reprogrammed from a patient’s own somatic cells, alleviating the
ethical and limited tissue availability with fetal cells and
minimizing complications associated with allogenic transplants.
Although reprogramming has historically used viral vectors, recent
advancements in microRNA technology has led to the develop-
ment of alternative transcription factor delivery methods that
have been reported to increase the conversion efficiency in vitro
and in vivo from somatic cells into functional dopaminergic
neurons and ameliorate motor symptoms in a model of PD.94
The next key consideration for development of a successful
regenerative strategy is the location of the graft. Based on the
success of the early studies, several graft locations have been
investigated, such as (1) in the striatum, (2) in the SNPc, or (3)
along the entire length of the nigrostriatal pathway. Many cell-
based transplantation strategies have primarily focused on using
intrastriatal dopaminergic grafts to restore the physiological levels
of dopamine within the striatum.53 As noted above, cells
implanted into the striatum may create new “factories” for
dopamine, but the cells do not receive the full suite of normal
inputs that regulate dopaminergic production and delivery in the
striatum. However, as striatal innervation is a critical requirement
for any potential cell source, “short-circuiting” the nigrostriatal
pathway is useful for developing effective stem cell therapies.
Intrastriatal transplantation of dopaminergic neurons in a NHP
model of Parkinsonism has been reported to demonstrate
extensive neurite outgrowth in the striatum and increased
dopamine uptake near the graft, resulting in significant
amelioration of the cardinal motor symptoms of PD.95–99
Despite these improvements, inconsistent functional recovery
in animal models and human studies has been reported, likely
owing to the variations in graft composition, low dopaminergic
neuron survival, poor neurite extension, minimal graft volume,
differing immunosuppressant regimes, and/or the inhibitory
microenvironment.68,81,100,101
Early intranigral transplantation studies largely failed because
long-distance axonal regrowth to the correct target(s) within the
CNS is limited.77,102,103 Despite the development of various
approaches to increase neurite outgrowth for targeted reinnerva-
tion, these strategies might result in the innervation of aberrant
targets and/or only attain sub-centimeter scale growth, thus
insufficient to reach what would be required in the human brain
(i.e., substantia nigra to striatum is at least 3 cm).76,96,104–106 For
example, a recent study reported that transplanation of human
ventral mesencephalic patterened progenitor cells established
extensive innervation towards appropriate forebrain targets and
reduction of behavioral deficits in rodents.80 Although these
findings are promising, off target growth is difficult to predict and/
or prevent with increased distance between the graft and
intended target, especially in larger animal models and humans.
However, a potentially transformative approach is being
advanced to create axon guidance paths via factors secreted by
host cells transfected with precise spatial precision (via stereotaxic
microinjection) to overexpress growth factors, creating chemo-
taxic gradients to drive long-distance, targeted axonal outgrowth
from endogenous and/or transplanted cells in the CNS.107,108
Although extremely promising, the scalability of this strategy to
centimeter scale axon paths will be paramount, as clinical
translation requires consistent and long-distance outgrowth with
precise targeted reinnervation to restore the full motor circuit.
To address the challenging regenerative distance, early studies
reported using embryonic striatal tissue as a “stepping stone” to
effectively enable targeted outgrowth from axons grafted in the
SNpc toward the graft, and ultimately the host striatum.109
Although this strategy appeared promising, in primate studies, the
attraction was greatly diminished with increasing distance
between the striatal “stepping stone” and the SNpc graft and
the preferential attraction to the striatal “stepping stone”
prevented outgrowth beyond the graft to the intended host
striatum.105 Other “bridging” strategies have been proposed, such
as fetal striatal tissue, fibroblast growth factor-4 secreting
schwannoma cells, GDNF-secreting Schwann cells, and kidney
tissue.101 Bridging the nigrostriatal pathway with growth factors or
cells alters the inhibitory microenvironment and provides a
supportive conduit for regenerating axons that effectively guides
immature axons from the SNpc to the DA-depleted striatum.
Alternative strategies have been explored to improve targeted
striatal reinnervation from fetal mesencephalic tissue grafted in
the substantia nigra, such as injecting kainate between the
midbrain and striatum to create a trophic environment for axonal
outgrowth.110 Although kainate administration was shown to
increase striatal dopamine release and reduced motor behavioral
deficits, kainate is an excitatory neurotoxin, thus significantly
limiting its potential regenerative strategy for patients with PD.111
Following this approach, a similar strategy has been investigated
using GDNF as an attractant for guiding transplanted axons from
the SNpc to the striatum. Administering a track of GDNF from the
fetal graft in the SNpc to striatum facilitated outgrowth and
improved rotational behavior in lesioned rats.112 This strategy was
adapted in a NHP model of PD that utilized viral-vector-mediated
overexpresion of GDNF in the striatum, enabling outgrowth from a
fetal graft in the SNpc toward the striatum. In this study, only a
few grafted dopaminergic axons innervated the striatum, how-
ever, these findings demonstrated neurotrophic supplementation
could enable targeted long-distance axonal outgrowth.106
Although the ideal location for cell transplantation is likely the
SNpc, successful striatal innervation in humans and NHPs requires
significantly more-targeted axonal outgrowth to achieve a
regenerative distance on the order of centimeters.61,113 Although
J.P. Harris et al.
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rodent transplantation studies have reported some improvement
in motor functionality, consistent recovery in humans would likely
require greater striatal reinnervation.
A promising strategy for reconstruction of the nigrostriatal
pathway utilizing multiple transplantations along the basal
ganglia circuitry has been reported to enable complex movement
patterns in models of PD.103,114,115 Extranigral transplants may
provide trophic support to otherwise denervated host neurons,
preventing widespread degeneration from second-order neuron
neurotransmitter depletion, thereby increasing the number of
potential targets for regenerating axons from dopaminergic
neurons transplanted in the SNpc. Reinnervating the extranigral
regions with dopaminergic neurons extending from the SNpc that
receive proper local inputs from other cell populations likely closes
the motor feedback loop, restoring the ability to generate
complex movement patterns.115 In a small open-label pilot study,
simultaneous nigral and striatal transplants resulted in significant
long-term clinical improvement of motor function in patients.116–118
Although intriguing as a regenerative strategy for PD, further
research is necessary to understand the exact mechanism behind
the impressive functional recovery and graft survival in rodents
and humans.
Another important consideration for development of cell-based
strategy for PD is the potential for graft-induced dyskinesia (GID).
Clinical trials with human embryonic tissue have demonstrated
that dopaminergic neurons can reinnervate the striatum, release
dopamine, and functionally integrate with the host brain.65
However, inconsistent functional recovery has been reported
across multiple clinical trials: although patients experienced
symptomatic relief ranging from nonexistent to significant
improvement, ~15% of patients developed off-phase dyskine-
sia.119 GID is an adverse effect likely caused by runaway dopamine
release and excessive outgrowth from the embryonic graft.100
Unlike the typical presentation of dyskinesias in patients with PD
caused by chronic L-DOPA administration, GID-induced abnormal
motor movements do not resolve with reduction and/or cessation
of L-DOPA treatment.120 Clinical findings from these studies
revealed an association between the development of GID and
the preoperative presentation of L-DOPA-induced dyskinesia (LID);
specifically there was a high incidence in patients who reported
severe motor fluctuations prior to transplantation.100
It has been suggested that biological rejection and persistent
low-grade inflammatory response might compromise the tissue
graft, leading to neurotransmitter dysregulation and ultimately
development of dyskinesias.121 This hypothesis originated from
the clinical observation that GIDs were only reported in patients
who either did not receive immunosuppression or only short-term,
low-dose immunosuppression after fetal engraftment.122 Other
studies have suggested the presence of serotonergic neurons in
the graft might play a critical role in the expression of GIDs.123 The
mechanism is still poorly understood, but it is likely that
serotonergic neurons were transplanted in the graft, which led
to a dysregulation of dopamine release. Indeed, in a clinical study
without any patients who developed GID, the postmortem
analysis revealed a 2:1 ratio of dopaminergic to serotonergic
neurons in the graft regions.118 Future clinical trials for fetal
engraftment might need to include immunosuppression and
avoid patients with established LID to increase the likelihood for
successful transplantation, a strategy that has been adopted by
various ongoing and upcoming clinical trials.124
Current state of clinical trials for PD
As described elsewhere in this review, early human fetal ventral
mesencephalic transplantation studies demonstrated graft survi-
val, reinnervation of the striatum, and functional restoration.
However, it has been argued that the development of adverse
events, such as GIDs, as well as failure of two double-blinded,
placebo-controlled studies to show differences between patients
transplanted with human fetal ventral mesencephalic tissue and
control-treated patients led to diminished interest in cellular
therapies for treatment of PD. In the last decade, thorough
reanalysis of these clinical observations provided the basis for
well-defined criteria in future clinical trials. This approach led to
the establishment of a European Union-funded multi-center team
(TRANSEURO) for a human ventral mesencephalic tissue trans-
plantation study that has focused on the implementation of well-
defined criteria, such as patient selection; tissue dissection,
preparation, and storage; grafting technique; immunosuppression
protocol; and experimental design. However, the TRANSEURO
study was unable to complete enrollment owing to scarcity of
human fetal tissue supply, leading to only 20 of the planned 90
patients undergoing transplantation.124
Human pluripotent stem cells (hPSCs) derived from ESC and
iPSCs are an attractive alternative cell source that avoids the
ethical and practical complications with fetal tissue. In 2014,
different teams from academic institutions across Europe, the
United States, and Japan began a new global initiative, GForce-PD,
that aims to advance hPSC-derived dopaminergic neurons to first-
in-human-clinical trials.124 Although human ESC-derived dopami-
nergic neurons likely have the capability to innervate the
putamen, some teams have chosen to use HLA-matched,
autologous iPSCs to avoid the need for immunosuppression.
Tissue engineering: combining cells and scaffolds
The objective of the field of neural tissue engineering is to utilize
biomaterial scaffolds and cell-based strategies in combination to
augment endogenous regeneration and/or to provide direct
replacement of neural cells and circuitry.125 Incorporated cell
types may include primary, stem, differentiated, genetically
engineered, autologous, allogeneic, or heterologous cells. Bioma-
terials utilized within the constructs often provide structure,
protect cells (implanted and/or host), and produce an environ-
ment in which cells can adhere, migrate, differentiate, and signal
to each other and to the host. Tissue-engineered constructs may
possess a defined architecture that not only facilitates integration
of the transplanted cells/processes with native tissue, but also
maintains their desired organization.126 This architecture may be
precisely engineered to match the structure and properties of the
tissue for integration: to provide directionality for infiltration from
implant to host, vice-versa, or both.5,127–129 Biomaterials may be
synthesized to promote desired cellular organizations or mechan-
ical properties (e.g., rigidity or elasticity) that are directionally
dependent (anisotropic). Likewise, gradients of factors, such as
growth factors and signaling molecules, may be used within
tissue-engineered scaffolds to generate anisotropic features. The
permissive microenvironment or proper matching of mechanical
features created by some biomaterial hydrogels may also improve
graft survival by influencing inflammatory reactions and minimiz-
ing the foreign body response.130
Previous research has indicated that long-distance axonal
outgrowth rarely occurs in the mature nervous system, and
therefore, to restore the full motor circuitry, alternative methods
are needed to repair the long-distance circuits disrupted in PD.
Biomaterial scaffolds are an alternative to facilitate long-distance
axonal outgrowth as they can aid in reconstructing the
nigrostriatal pathway by coaxing long-distance axonal outgrowth
from the SNpc to appropriate targets in the striatum (either by
endogenous or exogenous cells). Studies attempting to restore
long-distance axonal connections typically aimed to create a
permissive environment for axonal outgrowth, and/or augment
the intrinsic capacity of axons to regenerate.131,132 These
strategies most commonly involve biomaterial or cellular scaffolds
that provide growth-promoting cues or reduce inhibitory fac-
tors.133,134 Although notable, on their own, biomaterial scaffolds
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do not address the degeneration of source neuronal population(s).
Therefore, most scaffold approaches in PD are aimed at promoting
a hospitable environment for implanted cells rather than out-
growth from endogenous neurons.
An emerging strategy in neural tissue engineering involves the
development and application of so-called “living scaffolds”, which
are defined as constructs with a preformed, often anisotropic
architecture, consisting of living neural cells within a 3-D biomaterial
matrix.5,126,129,135 In particular, our group is pursuing the creation of
tissue-engineered “living scaffolds” for several applications, includ-
ing to provide regenerative pathways for axonal guidance or
neuronal migration, and also to directly replace neurons and axon
tracts in order to reconstruct degenerated neural cir-
cuits.5,125,126,128,129,135–137 Most relevant to PD, tailored constructs
may be developed to structurally and functionally emulate the
nigrostriatal pathway, toward the goal of replacing dopaminergic
neurons and their long axon tracts. This strategy is premised on the
plasticity of endogenous as well as tissue-engineered neural
networks, whereby neurons intrinsically have the ability to sense
and respond to local activity.138,139 It has been shown that
transplanted neurons are capable of receiving synaptic input from
local networks as well as propagating action potentials.140 Once the
appropriate synapses are established, preformed anatomically
inspired constructs could act as functional relays to transmit signals
between populations of previously disconnected cells.
As such, we are pursuing a novel regenerative medicine
solution whereby custom-built microtissue-engineered neural
networks (TENNs) are transplanted to physically replace SNpc
neurons and their long-distance axonal connections from the
SNpc to the striatum (Fig. 4). Micro-TENNs are precisely formed,
miniature constructs designed to mimic the systems-level
architecture of the nigrostriatal pathway: a discrete population
of dopaminergic neurons (Fig. 4b) extending long unidirectional
axonal tracts (Fig. 4a) within hydrogel micro-columns (Fig. 4c, d).
This tissue engineering-based strategy provides several advan-
tages. These constructs are fully grown in vitro prior to in vivo
implantation, allowing for verification of neuronal-axonal archi-
tecture, neuronal health, axonal projection length, and dopamine
production/release, as well as providing an opportunity to screen








Fig. 4 Reconstruction of the nigrostriatal pathway using microtissue-engineered neural networks (micro-TENNs). a Immunocytochemical
image of the axonal segment of a micro-TENN showing the robust outgrowth of dopaminergic axons in c, as labeled using an antibody for
tyrosine hydroxylase (TH; red). The hydrogel shell is highlighted with a dotted line. b Immunocytochemical image of the somatic end of a
uniaxial micro-TENN showing a large cluster of aggregated neurons in c, labeled with a Hoechst nuclear counterstain (blue) and using
antibodies for all neurons/axons (β-tubulin III; green) and dopaminergic neurons/neurites (TH; red), with an overlay of all three. c The cartoon
(left) and actual (right) unidirectional micro-TENN show the long-distance axonal outgrowth. The bolus of neurons is at the bottom with
axonal outgrowth projecting upwards. The actual micro-TENN has the same staining as b, and the hydrogel shell is highlighted with a dotted
line. d A diffusion tensor imaging representation of the long-distance axonal tracts (lilac) that connect discrete populations of neurons in the
human brain. This conceptual rendition shows how a unidirectional micro-TENN—consisting of a population of dopaminergic neurons
extending long, aligned processes—can be used to recreate the nigrostriatal pathway (green) that degenerates in PD. The magnification inset
in the lower right depicts axons (blue) in the substantia nigra functionally integrating with the transplanted dopaminergic neurons in the
micro-TENN (green). The magnification inset in the upper left depicts transplanted dopaminergic axons (green) functionally integrating with
neurons in the striatum (red). The micro-TENN implant theoretically recreates the full motor feedback circuit by receiving the stereotypical
inputs in the SNpc while projecting axons to the striatum to release regulated amounts of dopamine in that structure.
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undifferentiated and/or oncogenic cells in the case of stem cell-
derived constructs. The columnar hydrogel encasement initially
ensures the formation of the desired architecture during growth
in vitro while providing physical protection of the engineered
neuronal networks and axonal tracts during implantation and
degrading over weeks to gradually introduce the majority of the
construct surface area to the brain. This physical protection
coupled with the implantation of not only neurons and axons but
their 3-D microenvironment as well, may minimize neuronal/
axonal loss during transplant and promote survival and integra-
tion post transplant.
Therefore, micro-TENNs may have the capacity to restore the
nigrostriatal circuitry lost to PD by replacing the dopaminergic
neurons in the SNpc, enabling synaptic integration with inputs to
the SNpc, and restoring axonal terminals in the striatum.
Importantly, pathway reconstruction approaches such as the
micro-TENNs have the promise to restore the aspects of the motor
feedback path, a feat not possible with methods such as
pharmacological dopamine replacement therapy, DBS, or tissue
grafts in the striatum. As such, we are currently assessing the
ability of dopaminergic micro-TENNs to replace SNpc neurons and
restore dopaminergic inputs to the striatum in rat models. In
recent proof-a-concept study, microtissue-engineered neural
constructs containing a population of dopaminergic neurons on
one end and long axonal projections grown through a hydrogel
column were fabricated, mimicking the entire nigrostriatal path-
way.141 Cell source and construct length were evaluated and
evoked dopamine release was confirmed in vitro. These constructs
were stereotactically implanted en masse to mimic the nigros-
triatal pathway in a rodent model. At 1-month post implant,
histological data revealed neuronal survival and maintenance of
axonal architecture. Further studies investigating the synaptic
integration and amelioration of motor deficits in a rodent model
of PD are ongoing. If successful, dopaminergic micro-TENNs will
be the first strategy to facilitate nervous system repair by
simultaneously providing neuronal replacement and physically
re-creating long-distance axonal connections in the brain. In
addition, we are also establishing the future potential of
personalized micro-TENNs—built using neurons derived from a
patient’s own stem cells—as a potential solution to restore the
dopaminergic nigrostriatal pathway and ameliorate motor symp-
toms without the need for immunosuppression.
As discussed in previous sections, treatment of many non-motor
symptoms of PD has remained challenging owing to the
widespread dysregulation of the circuitry connecting basal ganglia,
prefrontal cortex, and limbic systems.15,19 To date, micro-TENNs
have been fabricated using dorsal root ganglia neurons, cerebral
cortical neurons (e.g., mixed glutamatergic and GABAergic),
embryonic rodent ventral mesencephalic dopaminergic neurons,
and human ESC-derived dopaminergic neurons.5,125,126,129,141–144
As our understanding of PD pathophysiology expands, it is
possible that multiple micro-TENNs could be transplanted to
reconnect different damaged regions, comprised of alternative
neuronal phenotypes, such as noradrenergic, serotoninergic, and
cholinergic cell types. However, it is difficult to predict how
transplant therapies, including either transplanted cells or path-
ways, such as micro-TENNs, could be used to recapitulate widely
dispersed innervation of cerebral cortex from cholinergic,
serotonergic, or noradrenergic brainstem nuclei.
Cell engineering and reprogramming
Promising recent work has utilized viral vectors to re-program
endogenous non-neuronal cells to become neurons.145 This
approach generally alters the gene expression of astrocytes—an
abundant glial cell type in the area of degeneration—to convert
them into neurons as a means for localized neuronal replacement.
Direct reprogramming of striatal astrocytes to dopaminergic
neurons in a rodent model of PD has been reported to improve
dopamine tone and reduce motor deficits.94 Although extremely
promising, conversion of striatal astrocytes would not reproduce
the nigrostriatal circuit, and conversion of nigral astrocytes would
require coupling with an axonal pathfinding strategy as described
above to elicit target connections to the striatum.
Cellular engineering strategies may also be advantageous for
cell transplants, with such genetic manipulation being employed
in vitro before in vivo implantation. For instance, specific genetic
alterations may be beneficial to improve survival, integration, and
efficacy. One type of modification could be to limit immunogeni-
city and thereby improve the survival and integration of the
cells.146 However, cell-based or tissue-engineered constructs
(either allogeneic or autologous) may eventually succumb to the
underlying pathology and degenerate similar to native tissue.
Indeed, recent studies have hypothesized that dysfunction of iron
metabolism in the substantia nigra might be implicated in the
degeneration of dopaminergic neurons and ultimately the
progression of PD.147 Although the susceptibility of transplanted
cellular constructs to the typical progression of PD pathology is
still unclear, dopaminergic neurons from tissue grafts can survive
up to 24 years in vivo despite ongoing degeneration of the native
dopaminergic system.52 However, in some patients with long-term
survival of fetal mesencephalic grafts, α-synuclein-positive Lewy
bodies were found in 1–5% of transplanted dopaminergic neurons
at 12–22 years and 12% in one patient at 24 years post
transplantation. Thus, the development of PD-resistant neurons
might be necessary to overcome this vulnerability, improve the
construct lifespan, and prevent α-synuclein aggregation by
augmenting the genes implicated in autophagy, α-synuclein
clearance, or decreased iron accumulation in the substantia
nigra.148,149 Furthermore, genetically enhanced dopaminergic
neurons engineered to increase dopamine production and/or
release could minimize the number of surviving cells necessary to
restore dopamine levels in the striatum, thus maximizing the
likelihood for successful innervation of the striatum, and
potentially halting the evolution of PD symptoms.
CLOSING: CHALLENGES AND OPPORTUNITIES
The classic motor symptoms of PD result from selective
degeneration of dopaminergic neurons in the SNpc, and
subsequently the disruption of key motor control circuits. This
circuit disruption results from loss of the finely tuned dopamine
delivery to the striatum via long-distance axonal projections.
Current treatments for PD, including the use of dopamine
replacement strategies and DBS, are aimed at treating symptoms
rather than the underlying neurodegeneration. Newer treatments
have focused on neuroprotection, but to date, no therapies have
been shown to clearly slow progression of neuronal degeneration
and hence motor symptoms.10,38 In addition, dopaminergic input to
the striatum requires continuous modulation and feedback from
other neural structures via SNpc inputs to alleviate potential
runaway dopamine excess and dystonia, a potential side effect
from cell transplants into the striatum.
To address these gaps in treatment, emerging regenerative
medicine solutions are being pursued to replace lost neurons and
axonal circuitry in PD. Indeed, the ultimate goal is to replace the
nigrostriatal pathway—dopaminergic neurons in the SNpc and
their axonal projections to the striatum—thereby allowing
implanted cells/tissue to be subject to the normal cellular
regulation that dopaminergic SNpc neurons are subject to in
order to “close the loop” and restore this crucial circuit for motor
control feedback. Reconstructing the pathway from the SNpc to
the striatum is the most likely means to provide dopaminergic
inputs that can be tuned and controlled by natural feedback
mechanisms present within the brain. On this front, our research
team is pursuing a tissue engineering-based strategy to
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accomplish this goal, as we are developing preformed, implan-
table column-like micro-constructs that mimic the architecture of
the nigrostriatal pathway: a discrete population of dopaminergic
neurons with unidirectional, long-projecting axonal tracts. The
method may be uniquely suited to simultaneously replace lost
dopaminergic neurons within the SNpc and recapitulate the full
nigrostriatal pathway—spanning several centimeters—to provide
naturally regulated dopaminergic inputs to the striatum. Unlike
DBS, which attempts to disrupt pathologic activity in the indirect
pathway, our preformed micro-constructs are themselves an
auxiliary pathway. In general, such precisely engineered constructs
may be highly controllable, where the number of neurons and
generation of dopamine can be known prior to implantation, thus
potentially ameliorating the inconsistency historically seen in fetal
tissue grafts.
In order to supply the requisite number of healthy dopaminer-
gic neurons needed for functional improvement in humans
(estimated to be 40,000–80,000 neurons), cell sources will need
to be significantly scaled up prior to clinical trials. Stem cells and
other expandable, self-renewing cell sources—whether allogeneic
or autologous—are promising to address these needs. Such
methods, while presenting challenges in controlling differentia-
tion, heterogeneity, and maturity, among others, will avoid the
limitations of fetal tissue grafts, specifically ethical considerations
and dearth of fetal source material. In particular, using emerging
iPSC methodology, a patient’s own cells could be efficiently
differentiated into dopaminergic neurons, thereby eliminating the
need for immunosuppression.82 Combined with tissue engineer-
ing methodology, such autologous stem cell sources may enable
the construction of patient-specific constructs tailored to their
particular extent of degeneration. Such next-generation constructs
may provide a transformative and scalable solution to directly
replace SNpc neurons, restore axon-based dopaminergic levels in
the striatum, and thereby alleviating the cause of motor
symptoms in PD. However, similar to the current limitations to
treatments for PD, potential benefits for cell-based neurorestora-
tive strategies would likely be dependent on the duration of
disease and thus degree of neurodegeneration. In the coming era
of restorative neurosurgery, emerging regenerative medicine
therapies may revolutionize PD treatment by permanently
reconstructing lost neuroanatomy and markedly improve out-
comes for millions of patients worldwide afflicted by PD.
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